Benefits and risks of intralesional corticosteroid injection in the treatment of dermatological diseases

• Published in: Clinical and experimental dermatology 1995-09, Vol.20 (5), p.363-370
• Main Authors: FFROOZ, A., TEHRANCHIA-NIA, Z., AHMED, A.R.
• Format: Article
• Language: English
• Subjects: Adrenal Cortex Hormones - administration & dosage; Adrenal Cortex Hormones - adverse effects; Biological and medical sciences; Humans; Injections, Intralesional; Medical sciences; Pharmacology. Drug treatments; Skin Diseases - drug therapy; Skin, nail, hair, dermoskeleton
• ISSN: 0307-6938; 1365-2230
• DOI: 10.1111/j.1365-2230.1995.tb01351.x

Summary Intralesional corticosteroid (CS) injections have been used to treat a variety of dermatological and non‐dermatological diseases with variable results. The purpose of the injection is to attain a high concentration of the drug at the diseased site, with minimal systemic absorption. Several CS preparations are available for intralesional injection, although triamcinolone derivatives have gained the widest usage in dermatology. The dose and the interval between injections depend on the type, size and severity of the lesion as well as the response to the previous injections. The most critical issue in the efficacy and also in the development of complications of the injections, is the method of injection. Several local and systemic side‐effects have been reported following intralesional injections, but most of them are rare or acceptable. Thus intralesional CS injection is an integral part of the clinical practice of dermatology. Since their introduction in 1951,1 intralesional CS injections have become an integral part of clinical practice in dermatology. They are used alone or in combination with other therapeutic modalities in the treatment of many skin diseases. The purpose of the injection is to attain a high local concentration of the CS at the diseased site, without significant systemic absorption, thus avoiding the numerous side‐effects associated with systemic administration. Intralesional CS injection may he a valuable therapeutic modality in situations where topical CS are not suitable for use, either because of low potency and inefficient epidermal harrier penetration or in clinical conditions associated with epidermal atrophy.